Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure

被引：9

作者：

Grenier, O ^{[1
]}

Pousset, F ^{[1
]}

Isnard, R ^{[1
]}

Kalotka, H ^{[1
]}

Carayon, A ^{[1
]}

Maistre, G ^{[1
]}

Lechat, P ^{[1
]}

Guerot, C ^{[1
]}

Thomas, D ^{[1
]}

Komajda, M ^{[1
]}

机构：

[1] HOP LA PITIE SALPETRIERE,PARIS,FRANCE

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1996年 / 10卷 / 05期

关键词：

endothelin; congestive heart failure; angiotensin converting enzyme inhibitor;

D O I：

10.1007/BF00050997

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Congestive heart failure (CHF) is a syndrome characterized by increased levels of angiotensin II (Ang II) and endothelin-1 (ET-1). In vitro, Ang II stimulates ET-1 release. The purpose of this study was to assess the effect of a single dose of an angiotensin-converting enzyme inhibitor (ACEI) captopril versus placebo on plasma endothelin concentration in human congestive heart failure. Captopril (25 mg, given orally) was compared with placebo in a group of 20 patients with systolic dysfunction in a double-blind randomized study. Plasma irET concentration was significantly increased in CHF patients compared with normal subjects (5.59 pg/ml +/- 0.35 vs. 3.58 pg/ml +/- 0.99, p < 0.0002). Despite the decrease in systolic blood pressure and the increase in plasma renin activity, suggesting a significant blockade of the renin-angiotensin system, no difference in plasma irET-1 was observed between captopril and placebo. Our results suggest that captopril does not acutely influence irET-1 plasma concentration in human CHF. These data do not support the hypothesis that the acute vasodilator effect of a single dose of 25 mg of captopril given orally involves modulation of the increased plasma concentration of endothelin observed in CHF.

引用

页码：561 / 565

页数：5

共 19 条

[1]

CLAVELL AL, 1994, CIRCULATION, V90, P452

[2] PLASMA ENDOTHELIN CORRELATES WITH THE EXTENT OF PULMONARY-HYPERTENSION IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].